Feed - Buzzberg

12:00
Aug 05 ◎

PODD FY2026 Q2 Watch

Insulet Corporation (PODD) FY2026 Q2 Earnings Call

PODD ABT ▾

Ashley McEvoy

Management is cutting full-year revenue guidance and citing execution failures in the Type 2 market, acknowledging a lack of visibility into retention/utilization trends.

"we should have identified the issue sooner and I'm confident in our ability to better serve the Type 2 community"

PODD WATCH

Ashley McEvoy

Management admits its guidance was set on flawed assumptions for Type 2 retention and is now assuming no improvement in attrition trends in the second half, suggesting the problem is partially structural. — This signals a material demand signal for CGM/diabetes ecosystem, potentially impacting companies like Abbott that view the Type 2 market as a key growth vector.

"We should have identified the issue sooner and I'm confident in our ability to better serve the Type 2 community."

ABT WATCH

HIGH

12:00
May 06 ◎

PODD FY2026 Q1 Watch

Insulet Corporation (PODD) FY2026 Q1 Earnings Call

PODD ABT DXCM ▾

Ashley McEvoy

Strong Q1 results, with 30% growth and robust margin expansion, prompt raising full-year guidance, indicating high confidence in sustained momentum.

"As a result, we are raising our full-year 2026 total company revenue growth guidance from 20% to 22% to 21% to 23%."

PODD WATCH

Ashley McEvoy

Abbott's Libre 3 Plus integration expands Insulet's addressable market to 450,000 additional users, highlighting the strategic partnership's importance.

"integrating with the Libre 3 Plus sensor this quarter will unlock the benefits of Omnipod 5 for the nearly 450,000 people..."

ABT WATCH

Ashley McEvoy

Dexcom's next-gen sensor is a key part of Insulet's integration roadmap, reinforcing their partnership.

"being first in line to integrate day one with sensors, like we're doing with the Dexcom 15 day."

DXCM WATCH

HIGH

13:00
Feb 18 ◎

PODD FY2025 Q4 Watch

Insulet Corporation (PODD) FY2025 Q4 Earnings Call

PODD DXCM ABT MDT TNDM ▾

Flavia Pease

Despite guided deceleration from comps, Insulet maintains strong growth outlook with 20-22% full-year revenue growth and continued margin expansion, indicating confidence in sustained demand.

"Our guidance reflects continued top tier market leading growth, but I know you will all ask me, why is growth decelerating?"

PODD WATCH

Eric Benjamin

Omnipod 5 is already compatible with Dexcom's new 15-day G7 sensor from day one, reducing risk of integration delays and preserving momentum. — This pre-emptive integration ensures no supply chain or compatibility issues that could slow Omnipod growth or sensor adoption.

"As a reminder, we were actually ready with the 15-day launch day one with Dexcom."

DXCM WATCH

Ashley McEvoy

Integration with Abbott's Libre 3+ expands Omnipod 5's CGM compatibility, reinforcing partnership and potentially boosting Abbott's sensor volume.

"And then as Ashley mentioned earlier, we began the limited market release of our Freestyle Libre Plus integration just recently"

ABT WATCH

Ashley McEvoy

Insulet is pivoting sales messaging to emphasize clinical performance (A1C reduction) as a counter to competitive claims, while maintaining its form-factor and user-experience edge. — Enhanced clinical pitch could protect market share against tube pump competitors and sustain growth from new MDI converts.

"I think that will be new information for many more clinicians. And then I'm going to come back to just continuing to build on our commercial prowess as we go, Larry."

MDT WATCH TNDM WATCH

HIGH

Feed — Buzzberg